keyword
MENU ▼
Read by QxMD icon Read
search

treatment hemoglobin prostate cancer

keyword
https://www.readbyqxmd.com/read/29790867/fluorine-18-fluorocholine-pet-ct-parameters-predictive-for-hematological-toxicity-to-radium-223-therapy-in-castrate-resistant-prostate-cancer-patients-with-bone-metastases-a-pilot-study
#1
Lavinia Vija Racaru, Mathieu Sinigaglia, Salim Kanoun, Fayçal Ben Bouallègue, Ilan Tal, Sévérine Brillouet, Mathilde Bauriaud-Mallet, Slimane Zerdoud, Lawrence Dierickx, Delphine Vallot, Olivier Caselles, Erwan Gabiache, Pierre Pascal, Frederic Courbon
PURPOSE: This study aims to predict hematological toxicity induced by Ra therapy. We investigated the value of metabolically active bone tumor volume (MBTV) and total bone lesion activity (TLA) calculated on pretreatment fluorine-18-fluorocholine (F-FCH) PET/CT in castrate-resistant prostate cancer (CRPC) patients with bone metastases treated with Ra radionuclide therapy. PATIENTS AND METHODS: F-FCH PET/CT imaging was performed in 15 patients with CRPC before treatment with Ra...
May 21, 2018: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/29731989/statin-use-and-survival-in-patients-with-metastatic-castration-resistant-prostate-cancer-treated-with-abiraterone-or-enzalutamide-after-docetaxel-failure-the-international-retrospective-observational-staben-study
#2
Jacob A Gordon, Carlo Buonerba, Gregory Pond, Daniel Crona, Silke Gillessen, Giuseppe Lucarelli, Sabrina Rossetti, Tanya Dorff, Salvatore Artale, Jennifer A Locke, Davide Bosso, Matthew Ivan Milowsky, Mira Sofie Witek, Michele Battaglia, Sandro Pignata, Cyrus Cherhroudi, Michael E Cox, Pietro De Placido, Dario Ribera, Aurelius Omlin, Gaetano Buonocore, Kim Chi, Christian Kollmannsberger, Daniel Khalaf, Gaetano Facchini, Guru Sonpavde, Sabino De Placido, Bernhard J Eigl, Giuseppe Di Lorenzo
Background: Statins may potentiate the effects of anti-hormonal agents for metastatic castration-resistant prostate cancer (mCRPC) through further disruption of essential steroidogenic processes. We investigated the effects of statin use on clinical outcomes in patients with mCRPC receiving abiraterone or enzalutamide. Materials and methods: This was a retrospective multicenter study including patients that received abiraterone or enzalutamide for mCRPC. The effect of concurrent statin use on outcomes was evaluated...
April 13, 2018: Oncotarget
https://www.readbyqxmd.com/read/29727761/systematic-review-and-meta-analyses-of-tranexamic-acid-use-for-bleeding-reduction-in-prostate-surgery
#3
REVIEW
Marcelo A Longo, Bárbara T Cavalheiro, Getúlio R de Oliveira Filho
BACKGROUND: Prostate cancer and benign prostatic hyperplasia have an increased incidence with aging. The most effective treatments are radical prostatectomy and transurethral resection of the prostate. To reduce perioperative bleeding in these surgeries, an approach is the use of tranexamic acid (TXA). Studies show that TXA is effective in reducing the blood loss and the need for transfusion in cardiac, orthopedic, and gynecological surgeries. In prostate surgeries, its efficacy and safety have not been established yet...
May 1, 2018: Journal of Clinical Anesthesia
https://www.readbyqxmd.com/read/29721063/photoacoustic-imaging-as-an-early-biomarker-of-radio-therapeutic-efficacy-in-head-and-neck-cancer
#4
Laurie J Rich, Austin Miller, Anurag K Singh, Mukund Seshadri
The negative impact of tumor hypoxia on radiotherapeutic efficacy is well recognized. However, an easy to use, reliable imaging method for assessment of tumor oxygenation in routine clinical practice remains elusive. Photoacoustic imaging (PAI) is a relatively new imaging technique that utilizes a combination of light and ultrasound (US) to enable functional imaging of tumor hemodynamic characteristics in vivo . Several clinical trials are currently evaluating the utility of PAI in cancer detection for breast, thyroid, and prostate cancer...
2018: Theranostics
https://www.readbyqxmd.com/read/29716525/prognostic-value-of-an-automated-bone-scan-index-for-men-with-metastatic-castration-resistant-prostate-cancer-treated-with-cabazitaxel
#5
Koichi Uemura, Yasuhide Miyoshi, Takashi Kawahara, Jikuya Ryosuke, Daisuke Yamashita, Shuko Yoneyama, Yumiko Yokomizo, Kazuki Kobayashi, Takeshi Kishida, Masahiro Yao, Hiroji Uemura
BACKGROUND: A computer-assisted diagnostic system for analyzing bone scans (BONENAVI) calculates the automated bone scan index (aBSI). Here we evaluated the aBSI as a prognostic imaging biomarker for men with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel. METHODS: We retrospectively analyzed 48 patients who received cabazitaxel for mCRPC and evaluated the ability of the aBSI to predict overall survival (OS). The Cox proportional hazards model was used to investigate the associations between baseline aBSI at cabazitaxel treatment and OS with the clinical variables as follows: age, number of cycles of docetaxel, serum prostate-specific antigen, hemoglobin (Hb), lactate dehydrogenase (LDH), and alkaline phosphatase...
May 2, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29700205/laboratory-based-biomarkers-and-liver-metastases-in-metastatic-castration-resistant-prostate-cancer
#6
Patrick M Cotogno, Lahiru K Ranasinghe, Elisa M Ledet, Brian E Lewis, Oliver Sartor
BACKGROUND: Metastatic castrate-resistant prostate cancer (mCRPC) patients with liver metastases have a poor prognosis. No large studies have investigated the clinical and biochemical parameters associated with liver metastases in this population. MATERIALS AND METHODS: Patient data made available via Project Data Sphere were collected from 1,281 men with mCRPC who were enrolled on to three phase III clinical trials for the treatment of their disease. Multiple logistic regression was performed on eight clinical and biochemical baseline variables to test their association with the presence of liver metastases on baseline radiographic imaging...
April 26, 2018: Oncologist
https://www.readbyqxmd.com/read/29681929/efficacy-and-safety-of-argon-plasma-coagulation-for-hemorrhagic-chronic-radiation-proctopathy-a-systematic-review
#7
REVIEW
Yanan Peng, Haizhou Wang, Juerong Feng, Shilin Fang, Meng Zhang, Fan Wang, Ying Chang, Xianyan Shi, Qiu Zhao, Jing Liu
Hemorrhagic chronic radiation proctopathy (CRP) is a common complication after pelvic radiotherapy in patients with prostate or gynecological cancers. This systematic review was conducted to evaluate the efficacy and safety of argon plasma coagulation (APC) in treating hemorrhagic CRP. The databases of PubMed, Embase, and Cochrane Library were searched for related studies from inception to July 2017. Finally, 33 studies were identified with a total of 821 hemorrhagic CRP patients. After APC treatment, hemoglobin levels increased from 7...
2018: Gastroenterology Research and Practice
https://www.readbyqxmd.com/read/29629866/prognostic-and-predictive-clinical-factors-in-patients-with-metastatic-castration-resistant-prostate-cancer-treated-with-cabazitaxel
#8
Daniel W Yokom, John Stewart, Nimira S Alimohamed, Eric Winquist, Scott Berry, Stacey Hubay, Jean-Baptiste Lattouf, Helene Leonard, Carla Girolametto, Fred Saad, Srikala S Sridhar
INTRODUCTION: Cabazitaxel is one of several treatment options available for patients with metastatic castration-resistant prostate cancer who have progressed on docetaxel. Little is known about clinical factors that influence prognosis or treatment response for patients receiving cabazitaxel. Identifying prognostic and predictive factors could contribute to the optimal selection of patients for treatment after docetaxel. METHODS: A retrospective review of patients enrolled on the cabazitaxel Canadian Early Access Program (C-EAP) was performed...
April 6, 2018: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/29382449/a-population-based-study-of-the-use-of-radium-223-in-metastatic-castration-resistant-prostate-cancer-factors-associated-with-treatment-completion
#9
Sunil Parimi, Erica Tsang, Abraham Alexander, Michael Mckenzie, Francois Bachand, Katherine Sunderland, Kim N Chi, Maria Aparicio, Daniel Worsley, Scott Tyldesley
INTRODUCTION: Radium 223 (Ra223) given for six cycles has proven efficacy in clinical trials, but its population-level generalizability has not been well-described. The objectives of this study were to describe population-based Ra223 use in the abiraterone and enzalutamide era and identify factors associated with completion. METHODS: All Ra223 patients at the British Columbia Cancer Agency between September 2013 and February 2016 were identified. Patients who completed <5 vs...
October 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/29324927/hematopoiesis-is-prognostic-for-toxicity-and-survival-of-223-radium-treatment-in-patients-with-metastatic-castration-resistant-prostate-cancer
#10
A Leisser, M Nejabat, M Hartenbach, H Duan, S F Shariat, G Kramer, M Krainer, M Hacker, A R Haug
OBJECTIVE: We evaluated the impact of pre-therapeutic hematopoiesis on survival, hematotoxicity (HT) and number of 223 Radium (223 Ra) treatments in patients with metastatic castration-resistant prostate cancer. SUBJECTS AND METHOD: Hemoglobin-levels (Hb), the number of platelets (Plts), leukocytes (Leuk), and survival data were collected in 56 patients treated with 223 Ra. Pre-therapeutic hematopoiesis as well as adverse events during and after therapy were scored (grade 0-4) according to the CTCAE recommendations...
September 2017: Hellenic Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/29290963/prognostic-factors-in-men-with-metastatic-castration-resistant-prostate-cancer-treated-with-cabazitaxel
#11
Bodine P S Belderbos, Ronald de Wit, Esther Oomen-de Hoop, Annemieke Nieuweboer, Paul Hamberg, Robbert J van Alphen, André Bergman, Nelly van der Meer, Sander Bins, Ron H J Mathijssen, Robert J van Soest
Background: Treatment selection for men with metastatic castration-resistant prostate cancer (mCRPC) has become increasingly challenging with the introduction of novel therapies at earlier disease stages. The purpose of this study was to identify prognostic factors for overall survival (OS) and PSA response in patients with mCRPC treated with cabazitaxel. Results: 224 mCRPC patients were included in the current analysis. In multivariable analysis, WHO performance status, baseline hemoglobin, alkaline phosphatase and albumin were all significantly associated with OS...
December 5, 2017: Oncotarget
https://www.readbyqxmd.com/read/29183960/radium-223-safety-efficacy-and-concurrent-use-with-abiraterone-or-enzalutamide-first-u-s-experience-from-an-expanded-access-program
#12
Oliver Sartor, Nicholas J Vogelzang, Christopher Sweeney, Daniel C Fernandez, Fabio Almeida, Andrei Iagaru, Alan Brown, Matthew R Smith, Manish Agrawal, Adam P Dicker, Jorge A Garcia, Jose Lutzky, Yu-Ning Wong, Oana Petrenciuc, Jeremy Gratt, Neal D Shore, Michael J Morris
BACKGROUND: In the phase III ALSYMPCA trial, metastatic castration-resistant prostate cancer (mCRPC) patients had few prior life-prolonging therapies. Following ALSYMPCA, which demonstrated radium-223 survival benefit, and before radium-223 U.S. commercial availability, an expanded access program (EAP) providing early-access radium-223 allowed life-prolonging therapies in current use. SUBJECTS, MATERIALS, AND METHODS: This phase II, open-label, single-arm, multicenter U...
February 2018: Oncologist
https://www.readbyqxmd.com/read/29181271/radium-223-in-metastatic-hormone-sensitive-high-grade-prostate-cancer-initial-experience
#13
García-Pérez Francisco Osvaldo, Medina-Ornelas Sevastián Salvador, Santana-Ríos Zael, Sobrevilla-Moreno Nora
Our study evaluates the feasibility of compassionate exemption of Radium-223 (223 Ra) treatment in metastatic hormone-sensitive high-grade prostate cancer (mHSHGPC) patients with concomitant androgen deprivation-therapy (ADT). Seven patients with mHSHGPC, were treated with six cycles of223 Ra plus ADT. All patients had undergone to18 F-NaF-PET/CT. A qualitative analyses of the18 F-NaF-PET/CT was performed in conjunction with Alkaline Phosphatase (ALP), Lactate-dehydrogenase (LDH) and Prostatic-Specific Antigen (PSA) values...
2017: American Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29111539/external-validation-and-newly-development-of-a-nomogram-to-predict-overall-survival-of-abiraterone-treated-castration-resistant-patients-with-metastatic-prostate-cancer
#14
Yun-Jie Yang, Guo-Wen Lin, Gao-Xiang Li, Bo Dai, Ding-Wei Ye, Jun-Long Wu, Hu-Yang Xie, Yao Zhu
Abiraterone acetate is approved for the treatment of castration-resistant prostate cancer (CRPC); however, its effects vary. An accurate prediction model to identify patient groups that will benefit from abiraterone treatment is therefore urgently required. The Chi model exhibits a good profile for risk classification, although its utility for the chemotherapy-naive group is unclear. This study aimed to externally validate the Chi model and develop a new nomogram to predict overall survival (OS). We retrospectively analyzed a cohort of 110 patients...
March 2018: Asian Journal of Andrology
https://www.readbyqxmd.com/read/28978007/differences-in-risk-factors-of-malignancy-between-men-and-women-with-type-2-diabetes-a-retrospective-case-control-study
#15
Mariusz Dąbrowski, Elektra Szymańska-Garbacz, Zofia Miszczyszyn, Tadeusz Dereziński, Leszek Czupryniak
BACKGROUND: The aim of this multicenter, retrospective, case-control study was to identify differences in risk factors of malignancy between men and women with type 2 diabetes. RESULTS: Among women the most prevalent malignancies were: breast and uterine cancers (35.6% and 14.4% respectively), while among men there were: colorectal and prostate cancers (24.5% and 13.3% respectively). In both gender metformin use was associated with lower cancer risk. Obesity and insulin treatment in dose-dependent and time-varying manner were associated with significantly increased risk of malignancy in females...
September 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28976393/-approach-to-peripheral-arterial-disease-in-the-elderly
#16
Ozan Onur Balkanay, Suat Nail Ömeroğlu
The prevalence of peripheral arterial disease, which usually develops on the basis of atherosclerosis and develops as a result of chronic arterial occlusive pathology, increases with age. Peripheral artery disease in the elderly patient population may be asymptomatic due to restrictive conditions associated with immobilization. Concurrent cerebrovascular disease and coronary artery disease risk and mortality rates are higher in elderly patients with peripheral artery disease. The life expectancy in patients with peripheral arterial disease is worse than in prostate cancer patients...
September 2017: Türk Kardiyoloji Derneği Arşivi: Türk Kardiyoloji Derneğinin Yayın Organıdır
https://www.readbyqxmd.com/read/28899723/characterization-of-differences-between-prostate-cancer-patients-presenting-with-de-novo-versus-primary-progressive-metastatic-disease
#17
Antoine Finianos, Kanika Gupta, Brandon Clark, Samuel J Simmens, Jeanny B Aragon-Ching
BACKGROUND: Men who present with metastatic disease can have de novo or primary progressive disease. We characterized and compared the outcomes between these 2 groups. PATIENTS AND METHODS: A retrospective cross-sectional analysis from a single institution of de novo versus primary progressive metastatic patients during a 2-year consecutive period was undertaken. Patient characteristics such as demographics, Gleason score, duration of hormone sensitivity, and treatment were obtained...
August 31, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28826933/safety-and-efficacy-of-docetaxel-bevacizumab-and-everolimus-for-castration-resistant-prostate-cancer-crpc
#18
Mitchell E Gross, Tanya B Dorff, David I Quinn, Patricia M Diaz, Olga O Castellanos, David B Agus
BACKGROUND: Previous data suggests that co-targeting mammalian target of rapamycin and angiogenic pathways may potentiate effects of cytotoxic chemotherapy. We studied combining mammalian target of rapamycin and vascular endothelial growth factor inhibition with docetaxel in castrate-resistant prostate cancer (CRPC). METHODS: Eligible patients had progressive, metastatic, chemotherapy-naive CRPC. Docetaxel and bevacizumab were given intravenously day 1 with everolimus orally daily on a 21-day cycle across 3 dose levels (75:15:2...
July 14, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28809079/changes-in-the-use-of-erythropoiesis-stimulating-agents-esas-and-red-blood-cell-transfusion-in-patients-with-cancer-amidst-regulatory-and-reimbursement-changes
#19
Prasad L Gawade, Jesse A Berlin, David H Henry, Dianne Tomita, Barry D Brooks, Janet Franklin, Brian D Bradbury, Cathy W Critchlow
PURPOSE: Evaluate changes in use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in cancer patients receiving myelosuppressive chemotherapy following regulatory and reimbursement actions. METHODS: Calendar year patient cohorts (2005-2013) with breast, colorectal, lung, multiple myeloma, non-Hodgkin lymphoma, ovarian, or prostate cancer and receiving myelosuppressive chemotherapy were identified within the Marketscan database. Incidence of ESA treatment and transfusion were estimated in each year, as was median number of ESA administrations...
August 14, 2017: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/28795333/patient-characteristics-and-overall-survival-in-patients-with-post-docetaxel-metastatic-castration-resistant-prostate-cancer-in-the-community-setting
#20
William K Oh, Raymond Miao, Francis Vekeman, Jennifer Sung, Wendy Y Cheng, Marjolaine Gauthier-Loiselle, Ravinder Dhawan, Mei Sheng Duh
It is unclear how treatment sequencing for metastatic castration-resistant prostate cancer (mCRPC) affects real-world patient outcomes. We assessed treatment sequences, patient characteristics and overall survival (OS) in post-docetaxel mCRPC patients. mCRPC patients receiving second-line cabazitaxel or androgen receptor-targeted therapy (ART; abiraterone/enzalutamide) post-docetaxel were identified using electronic medical records. OS was assessed from second-line therapy initiation using Cox regressions adjusting for: metastases; prostate-specific antigen (PSA); hemoglobin; alkaline phosphatase (ALP); albumin; second-line therapy initiation year...
August 10, 2017: Medical Oncology
keyword
keyword
79952
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"